Semaglutide risks and benefits: what the evidence actually shows

Step 1: what semaglutide is doing in your body, and why benefits build gradually

Semaglutide works by activating GLP-1 receptors in the brain and gut. The result is a quieter appetite, slower gastric emptying and, over time, a meaningful reduction in how much energy the body holds onto. The licensed dose for weight management (Wegovy) starts at 0.25 mg weekly and is increased by the prescriber roughly every four weeks up to a maintenance dose of 2.4 mg (or 7.2 mg, following the MHRA's approval of the higher-dose pen in April 2026).

The benefits in clinical trials are substantial. In the STEP 1 trial, published in the New England Journal of Medicine, adults using semaglutide 2.4 mg alongside lifestyle support lost an average of around 15% of their body weight over 68 weeks. That figure matters in health terms: reductions of that scale are associated with improvements in blood pressure, blood sugar regulation and joint load. Benefits rarely arrive fast, though. The early weeks are largely about the body adjusting, which is also when most side effects are most noticeable.

It's worth saying plainly: feeling uncertain before starting a medicine like this is entirely normal. Understanding the timeline helps. The slow dose escalation exists precisely because starting lower keeps most people's semaglutide risks and side effects mild enough to work through.

Step 2: the common side effects, what most people experience and how to manage them

The side-effect profile of semaglutide is GI-led. Nausea is the most frequently reported, followed by diarrhoea, constipation, vomiting, indigestion and burping. Fatigue, headache and dizziness appear less often. The NHS medicines page for semaglutide lists all reported effects alongside practical guidance on each.

Most of these effects are dose-dependent and time-limited. They are most pronounced after a dose increase and tend to ease within days to two weeks as the body adapts. Eating smaller meals, avoiding high-fat foods and staying well hydrated are the practical levers most people use during that window. If nausea is persistent or severe, a prescriber can slow the titration, staying at a lower dose longer before moving up is a recognised clinical response, not a failure.

Injection-site reactions (redness, itching, bruising at the abdomen, thigh or upper arm) are reported by some people, usually mild and self-resolving. Rotating the injection site each week reduces the risk.

Step 3: less common but serious risks, and exactly when to get medical help

Most people tolerate semaglutide well. A minority experience side effects that need clinical input promptly, and a very small number need urgent care. Knowing the difference matters.

Get urgent medical help if you develop: severe, persistent stomach pain that may spread to the back (with or without vomiting), this can be a sign of acute pancreatitis, which the MHRA flagged in its January 2026 Drug Safety Update on GLP-1 medicines; symptoms of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing, rapid heartbeat); or signs of severe dehydration from persistent vomiting or diarrhoea (very dark urine, dizziness on standing, confusion).

Contact your prescriber or GP if you notice: upper-right abdominal pain, nausea and fever that could suggest gallbladder problems (gallstones are more common during significant weight loss regardless of treatment); or unexpectedly low mood, thoughts of self-harm or changes in mental health that coincide with starting treatment.

The NHS semaglutide page and the Patient Information Leaflet in your Wegovy pack set out the full list of effects by frequency and severity. For side effects or suspect sellers, report to the MHRA at yellowcard.mhra.gov.uk.

Step 4: who the benefit-risk balance is (and isn't) appropriate for

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone is never the whole picture; a prescriber reviews your full medical history.

Semaglutide is not recommended during pregnancy, while breastfeeding or when trying to conceive. It is not licensed for anyone under 18. A personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 rules out its use entirely. Anyone with a history of pancreatitis will have that weighed carefully by a prescriber before a decision is made.

The NICE technology appraisal for semaglutide (TA875) sets out the benefit-risk reasoning behind NHS commissioning decisions, worth reading if you want to understand the evidence base at a clinical level. For a balanced look at the broader Wegovy risks and side effects landscape, our dedicated page covers the Wegovy-specific data in more depth. If you're weighing up whether treatment is right for you, our Wegovy overview sets out how the medicine works, what to expect week by week, and how the private route through a regulated pharmacy compares to the NHS pathway.

At nume, our prescribers discuss your health history, current medicines and any concerns about side effects as part of every free consultation. A GPhC-registered prescriber reads your answers (a real clinician, not automated software) and only approves treatment when the clinical picture supports it. That conversation is also where questions about the specific risks of semaglutide for your situation get a direct, personalised answer, rather than a generic one. You can also explore the semaglutide benefits and side effects page for a fuller breakdown of what the trial data shows across different outcome measures, and our guide to the risks of taking semaglutide covers the wider safety considerations worth reviewing before you begin. Our clinical team is available seven days a week for aftercare once treatment starts.